Strategic Collaboration
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
Bayer
PR-M11-20-030Dec 10, 2020
M&A
Bayer Acquires AskBio to Broaden Innovation Base in Cell and Gene Therapy
Bayer
PR-M10-20-15Oct 27, 2020
CRO
Bayer and Nuvisan Create New Research Unit in Berlin
Bayer
PR-M02-20-NI-013Feb 13, 2020
M&A
Wuxi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
WuXi Biologics
PR-M01-20-NI-025Jan 16, 2020
M&A
Yellow Wood Partners to Acquire Iconic Dr. Scholl’s™ Brand from Bayer
Bayer
PR-M07-19-NI-065Jul 25, 2019
Recall
Bayer Statement on Voluntary Recall of Two Lots of Kogenate® FS Antihemophilic Factor (Recombinant) in the United States
Nice Insight
PR-M07-19-NI-062Jul 24, 2019
FDA Approval
FDA Approves Bayer's Gadavist® (gadobutrol) Injection as the First and Only Contrast Agent for Use in Cardiac MR for Coronary Artery Disease
Bayer
PR-M07-19-NI-040Jul 16, 2019
Announcement
Bayer Supervisory Board Takes Action to Address the Glyphosate Litigation and Welcomes the Appointment of Ken Feinberg as Mediator
Bayer
PR-M07-19-NI-009Jul 05, 2019
Collaboration
Bayer and Foundation Medicine Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostics in Oncology
Bayer
PR-M05-19-NI-078May 29, 2019
Investment
Bayer Invests $150 Million to Build New Cell Culture Technology Center in Berkeley to Spur Innovation of Biotech Therapies
Bayer
PR-M05-19-NI-040May 14, 2019
Oncology
Bayer Announces Results of Sub-group Analysis for Vitrakvi® (larotrectinib) in Patients with NTRK Gene Fusion-Positive Metastatic Non-small Cell Lung Cancer (NSCLC)
Bayer
PR-M04-19-NI-047Apr 15, 2019
Corporate Culture
Bayer Only Life Science Company Named as a Most Reputable Company in Biggest-Ever Corporate Reputation Study in U.S.
Bayer
PR-M04-19-NI-036Apr 10, 2019
Oncology
Bayer to Obtain Full Rights to Global Development and Commercialization of Oncology Compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)
Bayer
PR-M02-19-NI-040Feb 19, 2019
Veterinary
Bayer Introduces Versatile New Option for Heartworm Prevention and Intestinal Parasite Control
Bayer
PR-M01-19-NI-062Jan 22, 2019
Prescribing Information
Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule
Bayer
PR-M01-19-NI-004Jan 02, 2019
Cutbacks and Divestitures Planned at Bayer
Nice Insight
PAO-M12-18-NI-004Dec 05, 2018
FDA Approval
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
Bayer
PR-M11-18-NI-104Nov 29, 2018
Appointment
Bayer appoints Sebastian Guth to lead Pharmaceuticals business in the Americas
Bayer: Science For A Better Life
PR-M10-18-NI-015Oct 03, 2018
Drug Development
Bayer Gets FDA Approval for Hemophilia A Drug
Emilie Branch
Pharma's Almanac
PAO-M09-18-NI-006Sep 06, 2018
Partnership
Broad and Bayer Expand Partnership, Launching New Research Effort to Develop Therapies for Heart Failure
Bayer
PR-M07-18-NI-005Jul 02, 2018